FMP
Frequency Therapeutics, Inc.
FREQ
NASDAQ
Inactive Equity
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
0.3 USD
0.0136 (4.54%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
179.66M
292.87M
254.1M
157.76M
99.21M
92.94M
87.08M
81.58M
76.43M
71.6M
-
63.01
-13.24
-37.91
-37.12
-6.31
-6.31
-6.31
-6.31
52.27M
113.72M
98.16M
28.51M
-
23.17M
21.7M
20.33M
19.05M
17.85M
29.1
38.83
38.63
18.07
-
24.93
24.93
24.93
24.93
49.77M
111.22M
96.06M
26.71M
-3.3M
21.76M
20.39M
19.1M
17.9M
16.77M
27.7
37.98
37.8
16.93
-3.33
23.42
23.42
23.42
23.42
2.51M
2.5M
2.1M
1.8M
3.3M
1.4M
1.31M
1.23M
1.15M
1.08M
1.4
0.85
0.83
1.14
3.33
1.51
1.51
1.51
1.51
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)